Frontlight ResearchEarly access
Taking people in DenmarkPhase 1
JFI447 Compared With FFG233 on Scans in People With Several Types of Solid Tumors
Tests JFI447 and how it shows on scans in adults with solid tumors.
Key facts
- Who runs it
- Novartis Pharma AG
- Where
- Copenhagen Oe and Odense C, DenmarkSee the 2 sites
- Trial code
- Registry title
- A clinical trial to learn about the effects of JFI447 and how it shows up in scans compared to FFG233 in people with solid tumors
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 22 people, planned
- Started
- 22 Sept 2026
- Expected to end
- 15 Nov 2027
- Type of study
- Interventional
- Record updated
- 10 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with certain metastatic solid tumors. It compares how JFI447 and FFG233 show up in scans.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Metastatic cancer: pancreatic ductal cancer (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer, triple-negative breast cancer (TNBC), colorectal cancer (CRC) or soft tissue sarcoma (STS).
Main reasons for not taking part
- Healthy volunteers cannot join.
Where in Denmark
- RigshospitaletCopenhagen Oe, DenmarkTaking people
- Odense University HospitalOdense C, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- JFI447 Compared With FFG233 on Scans in People With Several Types of Solid TumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 10 June 2026